Earnings Guidance
NeuroOne Medical Technologies Restates Q2 Results Due to Revenue Recognition Error, Reaffirms FY2026 Guidance
NeuroOne Medical Technologies will restate its fiscal second-quarter financials after an error overstated revenue by $0.5 million, but the company reaffirms its full-year product revenue guidance of at least $10.5 million.
Stonegate Capital Partners Highlights BlackSky's Gen-3 Commercialization Inflection and Upgraded Guidance
Stonegate Capital Partners updated coverage on BlackSky Technology, emphasizing accelerated Gen-3 commercialization with up to $160M in new wins, improved revenue visibility, and raised FY26 guidance.
DOUGLAS Group Lowers Profit Guidance Amid Market Slowdown and Consumer Uncertainty
DOUGLAS Group reports Q2 sales growth of 1.1% but a 5.1% drop in adjusted EBITDA, leading to a reduced full-year margin forecast as mature markets and weak consumer sentiment weigh on profitability.
PATRIZIA Reports Strong Financial Recovery and Raises Full-Year Guidance
PATRIZIA's significant EBITDA growth and improved investment activity signal a recovery in real asset markets as the company demonstrates resilience through cost discipline and strategic positioning.